ArticleFrontiers in oncology2026
Promising effects of high-intensity focused ultrasound combined with eribulin and sintilimab in a patient with advanced leiomyosarcoma: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Editorial: Innovative therapeutic approaches for complex cancers: exploring new strategies.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leiomyosarcoma (LMS) is an aggressive malignancy characterized by a high risk of recurrence and metastasis. The prognosis for advanced LMS remains poor due to limited effective treatment options. We report a case of advanced bladder LMS in a male patient whose disease progressed following standard therapies including surgery, first-line chemotherapy, and anlotinib. Disease stabilization was achieved after two cycles of eribulin combined with sintilimab. Subsequently, a partial response was achieved after the addition of high-intensity focused ultrasound (HIFU) to this regimen, and the response was maintained for 7.2 months with continued eribulin and sintilimab. This sustained disease control suggests that the integration of HIFU may augment the antitumor activity of systemic therapy in advanced LMS, warranting further investigation into this multimodal approach for patients refractory to conventional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.